Takeda
Stories
-
Takeda posts results of Phase 3 TAK-279 study in psoriasis
The study enrolled 18 participants and completed primary data collection on October 17, 2025. Results were first posted on ClinicalTrials.gov on November 4, 2026.
-
Takeda registers Phase 3b trial of Zasocitinib in psoriatic arthritis
Takeda plans to enroll 644 participants in a Phase 3b study of Zasocitinib (TAK-279) for active psoriatic arthritis, with a start date of January 11, 2027. The trial is expected to reach primary completion on April 18, 2030.
-
Results posted for TAK-881 PK, safety study in primary immunodeficiency diseases
Results for this study were first posted on ClinicalTrials.gov on September 30, 2026. The study enrolled 65 participants and completed primary data collection on January 20, 2026.